Literature DB >> 9658424

[Neonatal buprenorphine withdrawal syndrome, what is the right therapy?].

P Regini1, M Cutrone, F Donzelli, P G Flora, G Montesanto.   

Abstract

Buprenorphine is a new substance now widely used in detoxification of heroin addicts. In this report we describe the case of a newborn baby who suffered from a neonatal withdrawal syndrome characterized by a severe and prolonged course. This syndrome was followed by marked symptoms of impaired neurological development and by epilepsy. The ineffectiveness of methadone in relieving withdrawal symptoms from buprenorphine and its potential dangerous effects in this case are also outlined, whereas the efficacy of therapy with phenobarbytal is stressed. We think that this case is noteworthy, since the widespread use of buprenorphine among drug addicts will probably provoke an increase in the number of cases of buprenorphine withdrawal syndrome in the next years.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658424

Source DB:  PubMed          Journal:  Pediatr Med Chir        ISSN: 0391-5387


  3 in total

1.  Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.

Authors:  Isabelle Lacroix; Alain Berrebi; Daniel Garipuy; Laurent Schmitt; Yamina Hammou; Catherine Chaumerliac; Maryse Lapeyre-Mestre; Jean-Louis Montastruc; Christine Damase-Michel
Journal:  Eur J Clin Pharmacol       Date:  2011-05-03       Impact factor: 2.953

2.  Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone.

Authors:  Nathalie Colombini; Riad Elias; Muriel Busuttil; Myriam Dubuc; Marie-Ange Einaudi; Martine Bues-Charbit
Journal:  Pharm World Sci       Date:  2007-11-16

Review 3.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.